<DOC>
	<DOCNO>NCT01143051</DOCNO>
	<brief_summary>This study examine pharmacokinetic profile Armstrong 's proposed Epinephrine Inhalation Aerosol USP , HFA-MDI ( E004 ) , healthy male female adult volunteer . Safety E004 also evaluate , augment dose condition .</brief_summary>
	<brief_title>Pharmacokinetics ( PK ) Study Epinephrine Inhalation Aerosol Healthy Volunteers</brief_title>
	<detailed_description>This study randomize , evaluator-blind , single dose , three-arm , crossover , PK study , conduct ~18 healthy , male female , adult volunteer . PK study two dose strength ( Arm T1 Arm T2 ) . A currently market , non-labeled , Epinephrine CFC-MDI use Reference Control ( Arm C ) . - At Screening Visit begin Study Visit , subject train correct self-administration MDI . The following three randomized treatment self-administered , three Study Visits : - Treatment T1 : Ten ( 10 ) inhalation low dose E004 ( 125 mcg/inhalation ) , total 1.25 mg epinephrine ; - Treatment T2 : Ten ( 10 ) inhalation high dose E004 ( 160 mcg/inhalation ) , total 1.60 mg epinephrine ; - Treatment C : Ten ( 10 ) inhalation Epinephrine CFC-MDI ( 220 mcg/inhalation , total 2.2 mg epinephrine base equivalent ) . - PK blood sample take vein scheduled time point . - Safety parameter adverse drug event , , monitor document study visit . An End-of-Study ( EOS ) safety evaluation conduct .</detailed_description>
	<mesh_term>Epinephrine</mesh_term>
	<mesh_term>Racepinephrine</mesh_term>
	<mesh_term>Epinephryl borate</mesh_term>
	<criteria>Generally healthy , male female adult , 1830 yr age Screening ; Having clinically significant respiratory , cardiovascular systemic organic illness , per investigator discretion ; Women childbearing potential must nonpregnant , nonlactating , practice clinically acceptable form birth control ; Having properly consent satisfied inclusion/exclusion criterion require protocol . Other criterion apply . A recent significant smoking history ; Use prohibit drug failure observe drug washout restriction ; Having investigational drug/device study last 30 day prior Screening . Other criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Epinephrine</keyword>
	<keyword>Bronchodilator</keyword>
	<keyword>meter dose inhaler</keyword>
</DOC>